Nabla Bio vs Andson Biotech
Side-by-side comparison of AI visibility scores, market position, and capabilities
AI antibody design platform targeting undruggable GPCRs and ion channels; $37M raised with $550M+ in AstraZeneca, BMS, and Takeda partnership milestones led by Radical Ventures.
About
Nabla Bio is a Harvard spinout biotech company using AI-driven generative protein design to develop antibodies against multipass membrane proteins — a class of drug targets including GPCRs (G protein-coupled receptors), ion channels, and transporters that are implicated in numerous diseases but have been historically undruggable with antibody therapies due to their complex 3D structure embedded in the cell membrane. A Y Combinator graduate, Nabla Bio raised $37 million total including a $26 million Series A led by Radical Ventures, and secured strategic collaborations with AstraZeneca, Bristol Myers Squibb, and Takeda worth $550 million+ in upfront and milestone payments plus royalties.
Mass spectrometry sample prep and data science platform delivering 100x productivity for biopharma protein analysis; $9.1M from Merck Digital Sciences Studio, NIH, and YC at $1.8M revenue.
About
Andson Biotech is an Atlanta-based healthcare technology company providing mass spectrometry solutions for biopharma and biomanufacturing — offering the DynaCHIP hardware system (a novel mass spectrometry sample preparation platform) and DynaMARK data science module that together deliver up to 100x productivity improvements in protein and biomolecule analysis workflows compared to conventional mass spectrometry setups. Backed by Y Combinator, Merck Digital Sciences Studio, and NIH with $9.1 million raised, Andson achieved $1.8 million in revenue as of December 2024.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.